Neonatologists, intensivists, and plastic surgeons had the biggest increases: family physicians come in last….

We have now had about three months of use of the new medication, Invokana (canagliflozin). During this time many publications including our own newsletter have been running feature stories as well as ads for the product. This delivery of information is in addition to the field representatives calling on prescribers. …

When a new medication comes into the marketplace, some clinicians will begin prescribing it right away while others will wait for more information.

Dr. Bernstein reported that a treatment by a podiatrist probably caused an infection in a known diabetic. He alleges that the DPM used a “pumice” stone to grind it down and therefore caused the infection….

A position statement by controversial low-carb guru Richard Bernstein, MD has been circulating in various forms since August 2012, blaming all foot amputations in patients with diabetes on debridement of calluses. This past April 2013, Diabetes Care, the well-respected journal of the American Diabetes Association, republished the letter. The misinformation in this …

Stan Schwartz, MD, FACP, FACE has been doing clinical work for the University of Pennsylvania for many years. He has also worked with many obese patients as Director of the Obesity Program at the Cardiometabolic Diabetes Center. This week, after much persuasion from our publisher Steve Freed, Dr. Schwartz has …

Elizabeth Blair, MSN, PARN, BC, CDE The week’s excerpt addresses the following questions: How can you understand your patients’ behaviors? What is the emotional component? What lies behind a person’s choice or behavior? What expectations can you expect from your patients? How can you enhance the learning process? When should …

There have been a lot of additions to the diabetes drug armada over the past year and we have spent a lot of time helping you learn how best to use them. But over and over we have seen that no matter how good the drugs are, they just won’t …

FDA Approves Repaglinide (Generic Prandin)  FDA gives final approval for the generic form of Novo’s Prandin (repaglinide) to Sun Pharmaceutical Industries.

Complications-Centric Model for Care of the Overweight/Obese Patient  This algorithm is part of the new 2013 AACE Diabetes Management algorithm. This new part covers the care of the overweight/obese patient and can help you make the best decisions for your overweight patients. It answers questions such as when to start …